This article is more than 5 years old. Information may no longer be current.
Top five stories for World Autoimmune Arthritis Day
Click Here to Manage Email Alerts
VIDEO: Interstitial lung disease on the rise in patients with RA, despite better control of RA
DESTIN, Fla. — At the Congress of Clinical Rheumatology Annual Meeting, Iris Zink, MSN, RN, president of the Rheumatology Nurses Society, spoke about how the incidence of interstitial lung disease is on the rise, especially in men with aggressive rheumatoid arthritis, even though rheumatoid arthritis has become more well-controlled. Read More.
VIDEO: How to treat difficult patients with RA
DESTIN, Fla. — At the Congress of Clinical Rheumatology Annual Meeting, John J. Cush, MD, from the Baylor Institute, spoke about how to treat difficult patients with rheumatoid arthritis. Read More.
Real-world studies support the use of infliximab biosimilars
DESTIN, Fla. — Among the current therapeutic strategies for patients with rheumatoid arthritis are biosimilars, and real-world studies have supported the use of infliximab biosimilars, according to a presenter here at the Congress of Clinical Rheumatology Annual Meeting. Read More.
Study: TNF inhibitors linked with ‘slightly increased’ risk for extra-articular RA
According to a recently published analysis of a community-based cohort, patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors had “a slightly increased” risk for the development of severe extra-articular rheumatoid arthritis. Read More.
FDA accepts review of supplemental new drug applications of Xeljanz, Xeljanz XR for psoriatic arthritis
The FDA has accepted to review the supplemental new drug applications of Xeljanz at 5 mg twice daily, as well as Xeljanz XR extended release at 11 mg once daily, both for the treatment of patients with psoriatic arthritis, according to a company press release. Read More.
Collapse
Click Here to Manage Email Alerts